Septerna, Inc 10-Q for FY2026 Q3
Septerna, Inc. (SEPN)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
Septerna, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Septerna selected SEP-204 for Graves’ disease and thyroid eye disease, plans Phase 1 in the first quarter of 2027, and shifted SEP-631 away from a planned second half of 2026 Phase 2b trial in chronic spontaneous urticaria. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $18.88M
- down 12.2% from $21.5M a year earlier
- Net loss
- $26.59M
- compared with net income of $8.17M a year earlier
- Diluted EPS
- -$0.57
- compared with $0.18 a year earlier